Watch for Andexxa, the New Apixaban and Rivaroxaban Reversal Agent

July 2018

You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent....

Exclusive Subscriber Content

Best in class medication learning
Concise recommendations
Hundreds of practical resources

Subscribe Now Learn More

Login to access this content.

Login

Table of Contents

Anticoagulants Watch for Andexxa, the New Apixaban and Rivaroxaban Reversal Agent
Liver Disease Ensure Patients With Acute Variceal Bleeding Get Appropriate Treatment
Stroke Update Acute Stroke Protocols With the Latest Evidence
Transitions of Care Safely Transition Patients Taking Investigational Drugs at Home
Anesthesia Be Ready to Treat Toxicity From Local Anesthetics With IV Lipids
Practice Look for New Opportunities for IV-to-PO Conversions
Crohn s Disease Optimize Crohn's Maintenance Therapy During Hospitalization
New Drugs Substitute Xhance for Your Hospital's Intranasal Steroid
Infectious Diseases Watch for Acute Infections in Patients on Chronic Antibiotics
Aspirin Put the Aspirin and NSAID Interaction in Perspective